Impact of protease inhibitors on HIV-associated kaposi sarcoma incidence: A systematic review

Medicine & Life Sciences

• HIV Protease Inhibitors 100%
• Kaposi's Sarcoma 80%
• Systematic Reviews 50%
• Incidence 33%
• Protease Inhibitors 21%
• HIV 14%
• Reverse Transcriptase Inhibitors 12%
• Therapeutics 11%
• Risk Reduction Behavior 10%
• HIV Reverse Transcriptase 8%
• Retrospective Studies 7%
• Human Herpesvirus 8 6%
• Oncogenic Viruses 6%
• CD4 Lymphocyte Count 5%
• Social Adjustment 5%
• HIV Infections 4%
• Acquired Immunodeficiency Syndrome 4%
• Therapeutic Uses 4%
• PubMed 4%
• Epidemiology 4%
• Carcinogenesis 4%
• Cohort Studies 3%
• Costs and Cost Analysis 3%
• Neoplasms 1%